Methods of treating conditions associated with S1P1 receptor
By selecting appropriate dosages and treatment regimens, compound 1 addresses the cardiovascular adverse events associated with existing S1P1 receptor agonists, improves treatment tolerability and efficacy, and simplifies the tuning process.
Patent Information
- Application Number
- CN202411067321.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-01-08
- Filing Date
- 2020-01-08
- Publication Date
- 2024-11-19
AI Technical Summary
Existing S1P1 receptor agonists often cause adverse cardiovascular events when treating related conditions, making it difficult for patients to tolerate maintenance doses. The tuning process is complex and may lead to treatment interruption or the selection of other treatment options.
Compound 1 or its pharmaceutically acceptable salts, solvates or hydrates are used, with appropriate dosage and treatment regimens selected based on individual circumstances, avoiding repeated use with integrin receptor antagonists, especially for individuals who have not used this class of drugs or who have no history of pancolitis.
It improved patient tolerance to compound 1, reduced adverse cardiovascular events, simplified the tuning process, and enabled effective treatment of S1P1 receptor-related conditions.
Smart Images

Figure CN118976023A_ABST
Abstract
Description
[0001] The present invention is a divisional application of Chinese patent application No. 201780018986.7, filed on January 8, 2020. The name of the invention of the original application is “Methods for treating conditions associated with S1P1 receptors”. Technical Field
[0002] Provided are methods useful in treating sphingosine 1-phosphate subtype 1 (S1P1 or SIP1) receptor-associated disorders.
[0003] Sphingosine-1-phosphate (S1P) receptors 1-5 constitute a family of G protein-coupled receptors with seven transmembrane domains. These receptors are called S1P1 to S1P5 (formerly known as endothelial differentiation gene (EDG) receptors-1, -5, -3, -6 and -8, respectively; Chun et al., Pharmacological Reviews, 54: 265-269, 2002), and are activated by binding to sphingosine-1-phosphate (which is produced by phosphorylation catalyzed by sphingosine kinase of sphingosine). S1P1, S1P4 and S1P5 receptors activate Gi but not Gq, while S1P2 and S1P3 receptors activate both Gi and Gq. S1P3 receptors, but not S1P1 receptors, respond to agonists that increase intracellular calcium.
[0004] In view of the importance of S1P treatment l S1P is useful in treating receptor-related disorders l The demand for agonists is growing, compound (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1, APD334), or a pharmaceutically acceptable salt, solvate or hydrate thereof,
[0005]
[0006] It has emerged as an important new compound, see PCT patent application serial number PCT / US2009 / 004265, which is hereby incorporated by reference in its entirety. Compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof is an investigational drug candidate intended for the treatment of sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorders.
[0007] Many S1P l Agonists cause side effects, and particularly cardiovascular-related adverse events, which require physicians to slowly titrate patients to a maintenance dose. This titration period may take weeks or even a month. The complexity and duration of the titration regimen may cause patients to prematurely discontinue treatment before reaching a maintenance dose, or cause physicians to prefer other treatment options.
[0008] There is a need for effective treatment with Compound 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in appropriate patient populations. The present disclosure satisfies this need and also provides related advantages.
[0009] Citation of any reference throughout this application shall not be construed as an admission that such reference is prior art to the present application. Summary of the invention
[0010] Described herein are the results of clinical studies conducted with Compound 1 and the finding that no improvement was seen in individuals who had previously used vedolizumab or had a history of pancolitis. Pancolitis (also known as generalized colitis, pancolitis, or pan-ulcerative colitis) is a form of ulcerative colitis that spreads throughout the large intestine.
[0011] Provided herein is a method for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated condition in a subject in need thereof, comprising the steps of: selecting a subject who has not been previously treated with a therapeutically effective amount of an integrin receptor antagonist; and administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0012] Additionally provided is a method of treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated condition in a subject in need thereof, comprising the steps of: selecting a subject who has not been previously treated with an integrin receptor antagonist; and administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0013] Also provided is a method of treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related condition in a subject in need thereof, comprising the steps of: determining whether the subject has been treated with an integrin receptor antagonist; and, if the subject has not been treated with the integrin receptor antagonist, administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopentyl in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1. or a pharmaceutically acceptable salt, solvate or hydrate thereof, or, if the subject has been treated with the integrin receptor antagonist, not administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0014] Also provided is a method for treating sphingosine 1-phosphate subtype 1 (S1P1) receptor-related symptoms in an individual in need thereof, comprising the steps of: selecting an individual who does not suffer from pancolitis; and administering to the individual a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0015] Also provided is a method for treating sphingosine 1-phosphate subtype 1 (S1P1) receptor-related symptoms in an individual in need thereof, comprising the steps of: selecting an individual who does not have a history of pancolitis; and administering to the individual a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0016] Also provided is a method of treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related symptom in a subject in need thereof, comprising the steps of: determining whether the subject has a history of pancolitis; and administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopentadienyl in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1 if the subject does not have a history of pancolitis. [b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof, or, if the individual has a history of pancolitis, not administering a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0017] Further provided herein is a method of treating a subject with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, comprising the steps of: selecting a subject suffering from ulcerative proctitis, proctosigmoiditis, or left-sided colitis; and administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0018] These and other aspects of the invention disclosed herein will be set forth in greater detail as the patent publication proceeds. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 The results of the assay described in Example 2 are shown for eltramod (L-arginine salt of Compound 1), ozanimod, (Tofacitinib citrate), (vedolizumab), (golimumab) and Comparison of the percentage of patients with endoscopic improvement, defined as the proportion of patients with a Mayo subscore of 0 or 1, with adalimumab (adalimumab).
[0020] Figure 2 The results of the assay described in Example 2 are shown for eltramod (L-arginine salt of Compound 1), ozanimod, (Tofacitinib citrate), (vedolizumab), (golimumab) and The percentage of patients with clinical remission (defined as the total Mayo Clinic score) after adalimumab < 2 and no sub-score >1).
[0021] Figures 3A-3D Subgroup analyses of placebo-adjusted changes (90% confidence intervals) at week 12 for the eltramod 2 mg group in the trial described in Example 2 are shown. Improvement in modified MCS (3A and 3C) and the proportion of patients achieving clinical remission (3B and 3D) are shown for baseline disease characteristics (3A and 3B) and prior or concurrent therapy (3C and 3D). Values less than 0.0 favor placebo, whereas values greater than 0.0 favor eltramod ( Figure 3A and Figure 3C ). Values less than 0 favor placebo, whereas values greater than 0 favor eltramodulide ( Figure 3B and Figure 3D ). Sample size n = eltramod 2 mg group, placebo group. CRP = C-reactive protein; CS = corticosteroids; IS = immunosuppressants; MCS = Mayo Clinic score; TNFα = tumor necrosis factor α; UC = ulcerative colitis. DETAILED DESCRIPTION
[0022] As used in this specification, the following words and phrases are generally intended to have the meanings as set forth below, except where the context in which they are used indicates otherwise.
[0023] Compound 1: As used herein, "Compound 1" means (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, including crystalline forms thereof. As a non-limiting example, Compound 1 may exist in an anhydrous, non-solvated, crystalline form as described in WO 2010 / 011316 (incorporated herein by reference in its entirety). As another non-limiting example, the L-arginine salt of Compound 1 may exist in an anhydrous, non-solvated, crystalline form as described in WO 2010 / 011316 and WO 2011 / 094008 (each of which is incorporated herein by reference in its entirety). As another non-limiting example, the calcium salt of Compound 1 may exist in a crystalline form as described in WO 2010 / 011316 (incorporated herein by reference in its entirety).
[0024] Administration: As used herein, "administering" means providing a compound or other therapy, remedy or treatment such that the subject internalizes the compound.
[0025] Prescribing: As used herein, "prescribing" means ordering, authorizing or recommending the use of a drug or other therapy, treatment or therapy. In some embodiments, a health care practitioner may verbally suggest, recommend or approve the use of a compound, a dosing regimen or other treatment for an individual. In this case, the health care practitioner may or may not provide a prescription for the compound, dosing regimen or treatment. In addition, the health care practitioner may or may not provide the recommended compound or treatment. For example, the health care practitioner may suggest where the individual can obtain the compound instead of providing the compound. In some embodiments, the health care practitioner may provide a prescription for a compound, dosing regimen or treatment to the individual. For example, the health care practitioner may provide a written or oral prescription to the individual. The prescription can be written on paper or on an electronic medium such as a computer file, for example, on a handheld computer device. For example, a health care practitioner can transform a piece of paper or electronic media into a prescription for a compound, dosing regimen or treatment. In addition, the prescription can be (orally) stated, faxed (written) or submitted electronically to a pharmacy or dispensing office via the Internet. In some embodiments, a sample of an individual compound or treatment can be given. As used herein, administration of a sample of a compound constitutes an implicit prescription of the compound.Different healthcare systems around the world use different methods for prescribing and / or administering compounds or treatments, and the present disclosure encompasses these methods.
[0026] The prescription may include, for example, the name and / or identifying information of the individual, such as date of birth. Also, for example, the prescription may include: the name of the drug, the strength of the drug, the dosage, the frequency of administration, the route of administration, the amount or quantity to be dispensed, the number of refills, the name of the physician, the physician's signature, etc. Also, for example, the prescription can include a DEA number or a state number.
[0027] A healthcare practitioner can include, for example, a physician, nurse, nurse practitioner, or other related healthcare professional who can prescribe or administer a compound (drug) for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder. In addition, a healthcare practitioner can include anyone who can recommend, prescribe, manage, or prevent an individual from receiving a compound or drug, including, for example, an insurance provider.
[0028] PREVENT / PREVENTING / PREVENTION: As used herein, the term "prevent / preventing / prevention" such as preventing the occurrence or onset of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder or one or more symptoms associated with a particular disorder does not necessarily mean to completely prevent the disorder. For example, the term "prevent / preventing / prevention" means administering therapy on a preventive or prophylactic basis to an individual who may eventually develop at least one symptom of a disease or condition but has not yet done so. These individuals can be identified based on risk factors known to be associated with the subsequent occurrence of the disease. Alternatively, preventive therapy can be administered as a preventive measure without prior identification of risk factors. Delaying the onset of at least one symptom can also be considered prevention or prophylaxis.
[0029] Treat / treating / treatment: As used herein, the term "treat / treating / treatment" means administering therapy to an individual who has displayed at least one symptom of a disease or condition or has previously displayed at least one symptom of a disease or condition. For example, "treating" can include alleviating, alleviating, or ameliorating symptoms of a disease or condition, preventing other symptoms, ameliorating the underlying metabolic causes of symptoms, inhibiting a disease or condition, such as arresting the development of a disease or condition, relieving a disease or condition, causing regression of a disease or condition, relieving a condition caused by a disease or condition, or stopping symptoms of a disease or condition. For example, the term "treat" with respect to a symptom means a reduction in the severity of one or more symptoms associated with that particular symptom. Thus, treating a disorder does not necessarily mean a reduction in the severity of all symptoms associated with the disorder, and does not necessarily mean a complete reduction in the severity of one or more symptoms associated with the disorder.
[0030] Tolerance: As used herein, a subject is said to "tolerate" a dose of a compound if administration of the dose to the subject does not result in an unacceptable adverse event or combination of unacceptable adverse events. One skilled in the art will appreciate that tolerance is a subjective measure, and what is tolerable to one subject may not be tolerated to another. For example, one subject may not be able to tolerate headaches, while a second subject may find headaches tolerable but not vomiting, but for a third subject, headaches alone or vomiting alone are tolerable, but the subject cannot tolerate the combination of headaches and vomiting, even if each is less severe than when experienced alone.
[0031] Adverse events: As used herein, "adverse events" are adverse medical events associated with treatment with Compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof. In one embodiment, the adverse event is selected from: leukopenia, constipation, diarrhea, nausea, abdominal pain, neutropenia, vomiting, back pain and menstrual abnormalities. In one embodiment, the adverse event is heart block, for example, first degree atrioventricular heart block. In one embodiment, the adverse event is an acute decrease in heart rate. In one embodiment, the adverse event is an abnormal lung function test result, such as FEV1, FVC less than 80%. In one embodiment, the adverse event is an abnormal liver function test, such as elevated ALT&AST>2X ULN. In one embodiment, the adverse event is macular edema.
[0032] In need of treatment and in need thereof: As used herein, "in need of treatment" and "in need thereof" are used interchangeably in reference to treatment to mean a judgment made by a caregiver (e.g., in the case of humans, a physician, nurse, nurse practitioner, etc.) that an individual requires or will benefit from treatment. This judgment is made based on a variety of factors within the caregiver's area of expertise, but includes the knowledge that the individual is ill or will become ill due to a disease, condition, or disorder that can be treated by the compounds of the invention. Thus, the compounds of the invention can be used in a protective or preventative manner; or the compounds of the invention can be used to alleviate, inhibit, or ameliorate a disease, condition, or disorder.
[0033] Acute heart rate reduction: As used herein, "acute heart rate reduction" means that the heart rate decreases from normal sinus rhythm to, for example, 10 beats per minute (bpm) or more, such as less than about 5 bpm, such as less than about 4 bpm or less than about 3 bpm or less than 2 bpm, i.e., reaches a maximum value within a few hours (e.g., 1-3 hours) after administration of the drug, and thereafter the heart rate returns to the value before administration.
[0034] Normal sinus rhythm: As used herein, "normal sinus rhythm" means the sinus rhythm of an individual when not undergoing treatment. The assessment of normal sinus rhythm is within the capabilities of a physician. Normal sinus rhythm will typically produce a heart rate in the range of 60-100 bpm.
[0035] Dose: As used herein, "dose" means the amount of Compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof, administered to an individual at a specific time for the treatment or prevention of a disease or disorder.
[0036] Standard dose: As used herein, "standard dose" means the dose of compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof for treating or preventing a disease or condition administered to an individual. In some embodiments, the administration of a standard dose achieves a target reduction in peripheral blood lymphocyte counts, such as a baseline reduction of at least 35%, such as at least 40%, such as at least 45%, such as at least 50%, such as at least 55%, such as at least 60%, such as at least 65%, such as at least 70%. In some embodiments, the administration of a standard dose achieves a baseline reduction of about 35% to about 70%, such as about 40% to about 65%, such as about 50% to about 65%. In some embodiments, the administration of a standard dose achieves a target peripheral blood lymphocyte count, such as less than 1000 lymphocytes per microliter, such as 400-800 lymphocytes per microliter. The target dose may vary depending on the nature and severity of the disease to be treated.
[0037] Mayo Clinic Score (MCS): As used herein, "Mayo Clinic Score" or "MCS" means an instrument designed to measure the disease activity of ulcerative colitis and consists of up to 4 sub-scores: stool frequency, rectal bleeding, the results of flexible rectosigmoidoscopy, and the overall assessment of the physician, each component ranging from 0 to 3 (0 = normal, 1 = mild, 2 = moderate, 3 = severe). Therefore, the total score ranges from 0 to 12, with higher scores indicating more severe disease. The 6-point Mayo score is based on the stool frequency and rectal bleeding PROs collected daily using electronic medical records, and does not include the results of endoscopy and the overall assessment of the physician. The 3-point Mayo score is based on the results of stool frequency, rectal bleeding, and endoscopy, and the total score ranges from 0 to 9. The 2-point Mayo score is based on the results of rectal bleeding and endoscopy, and the total score ranges from 0 to 6. The physician's global assessment endorsed the other three standard examination results of the MCS, the individual's daily record of abdominal discomfort and general health status, and other observations, such as physical examination results and the individual's presentation.
[0038] Mildly to moderately active ulcerative colitis: As used herein, "mildly to moderately active ulcerative colitis" means ulcerative colitis characterized by a 4-component MCS of 4 to 10.
[0039] Moderately to severely active ulcerative colitis: As used herein, "moderately to severely active ulcerative colitis" means ulcerative colitis characterized by a 3-component MCS of 4 to 9, including an endoscopic score ≥ 2 and a rectal bleeding score ≥ 1. The 3-component MCS uses 3 of the 4 components of the full MCS (endoscopic findings, rectal bleeding, and stool frequency).
[0040] Clinical remission: As used herein, "clinical remission" with respect to ulcerative colitis means a 3-point Mayo Clinic score as follows: an endoscopic score (using flexible proctosigmoidoscopy) of 0 or 1, a rectal bleeding score of 0, and a stool frequency score of 0 or 1, with a decrease of ≥1 point from the baseline subscore.
[0041] Clinical response: As used herein, "clinical response" with respect to ulcerative colitis means a decrease in the 3-point Mayo Clinic score of ≥2 points and a decrease of ≥30% from baseline with a decrease in the rectal bleeding score of ≥1 or an absolute rectal bleeding score of 0 or 1.
[0042] Endoscopic improvement: As used herein, "endoscopic improvement" with respect to ulcerative colitis refers to ulcerative colitis characterized by a Mayo endoscopic subscore (the result of examination using a flexible proctosigmoidoscopy) of ≤ 1.
[0043] Endoscopic remission: As used herein, "endoscopic remission" with respect to ulcerative colitis means ulcerative colitis characterized by a flexible proctosigmoidoscopy result of a Mayo Clinic score = 0.
[0044] Improvement in rectal bleeding: As used herein, "improvement in rectal bleeding" with respect to ulcerative colitis means a change from baseline of <0.
[0045] Histologic healing: As used herein, "histologic healing" with respect to ulcerative colitis means a score < 3.1 on the Geboes Index.
[0046] Improvement in stool frequency: As used herein, "improvement in stool frequency" with respect to ulcerative colitis means a change from baseline of <0.
[0047] 5-aminosalicylate: As used herein, "5-aminosalicylate" refers to a class of drugs that include, e.g. (Mesalin), (balsalazide disodium), (mesalazine), (Mesalin) and (Olsalazine).
[0048] Immunosuppressants: As used herein, "immunosuppressants" refers to a class of drugs that include e.g. (azathioprine), (azathioprine), (cyclosporine), (cyclosporine) and (cyclosporine).
[0049] Glucocorticosteroids: As used herein, "glucocorticosteroids" refers to a class of drugs that include e.g. (budesonide); (prednisone), (methylprednisolone) and hydrocortisone.
[0050] TNFα antagonist: As used herein, "TNFα antagonist" or "tumor necrosis factor-α antagonist" refers to a class of drugs that include, e.g. (golimumab), (infliximab) and (Adalimumab).
[0051] Integrin receptor antagonists: As used herein, "integrin receptor antagonists" or "integrin antagonists" refer to a class of drugs that include, e.g. (vedolizumab).
[0052] Pharmaceutical composition: As used herein, "pharmaceutical composition" means a composition comprising at least one active ingredient (such as Compound 1); including but not limited to salts, solvates and hydrates of Compound 1, whereby the composition is suitable for studying a specific effective result in a mammal (such as but not limited to humans). One of ordinary skill in the art will understand and appreciate the techniques suitable for determining whether an active ingredient has a desired effective result according to the needs of the technician.
[0053] Agonist: As used herein, "agonist" means a moiety that interacts with a G protein-coupled receptor (such as an S1P1 receptor) and activates the G protein-coupled receptor, such as being able to thereby elicit a physiological or pharmacological response sign of the receptor. For example, an agonist activates an intracellular response after binding to a receptor, or enhances GTP binding to the membrane. In certain embodiments, the agonist of the present invention is an S1P1 receptor agonist that is capable of promoting sustained S1P1 receptor internalization (see, e.g., Matloubian et al., Nature, 427, 355, 2004).
[0054] Antagonist: As used herein, "antagonist" means a moiety that competitively binds to a receptor at the same site as an agonist (e.g., an endogenous ligand), but which does not activate the intracellular response elicited by the active form of the receptor and thereby inhibits the intracellular response of an agonist or partial agonist. In the absence of an agonist or partial agonist, an "antagonist" does not reduce the baseline intracellular response.
[0055] Hydrate: As used herein, "hydrate" means a compound of the present invention or a salt thereof that further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.
[0056] Solvate: As used herein, the term "solvate" means a compound of the invention or a salt thereof, which further includes a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. Preferred solvents are volatile, non-toxic and / or acceptable for administration to humans in trace amounts.
[0057] Compounds according to the present invention may optionally exist as pharmaceutically acceptable salts, and the salts include pharmaceutically acceptable acid addition salts prepared from pharmaceutically acceptable nontoxic acids (including inorganic acids and organic acids). Representative acids include, but are not limited to, acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, vinylsulfonic acid, dichloroacetic acid, formic acid, fumaric acid, gluconic acid, glutamic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, oxalic acid, p-toluenesulfonic acid, etc., such as Berge et al., Journal of Pharmaceutical Sciences, 66:1-19 (1977) those pharmaceutically acceptable salts listed, which are incorporated herein by reference in their entirety.
[0058] Acid addition salts can be obtained as the direct product of compound synthesis. In an alternative, the free base can be dissolved in a suitable solvent containing an appropriate acid and the salt can be isolated by evaporating the solvent or otherwise separating the salt and solvent. The compounds of the present invention can form solvates with standard low molecular weight solvents using methods known to those skilled in the art.
[0059] It should be understood that when the phrase "pharmaceutically acceptable salts, solvates and hydrates" or the phrase "pharmaceutically acceptable salts, solvates and hydrates" is used in reference to Compound 1, it includes pharmaceutically acceptable solvates and / or hydrates of Compound 1, pharmaceutically acceptable salts of Compound 1, and pharmaceutically acceptable solvates and / or hydrates of pharmaceutically acceptable salts of Compound 1. It should also be understood that when the phrase "pharmaceutically acceptable solvates and hydrates" or the phrase "pharmaceutically acceptable solvates and hydrates" is used in reference to Compound 1 as a salt, it includes pharmaceutically acceptable solvates and / or hydrates of such salts.
[0060] It will be apparent to those skilled in the art that the dosage forms described herein may include Compound 1 or a pharmaceutically acceptable salt or solvate or hydrate thereof as an active ingredient. In addition, various hydrates and solvates of Compound 1 and their salts will be useful as intermediates for preparing pharmaceutical compositions. Typical methods for preparing and identifying suitable hydrates and solvates other than those mentioned herein are well known to those skilled in the art; see, for example, KJ Guillory, "Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids," in Polymorphism in Pharmaceutical Solids, ed. Harry G. Britain, Vol. 95, Marcel Dekker, Inc., New York, 1999, pp. 202-209. Thus, one aspect of the present disclosure relates to methods of prescribing and / or administering hydrates and solvates of Compound 1 and / or pharmaceutically acceptable salts thereof, which can be separated and characterized by methods known in the art, such as thermogravimetric analysis (TGA), TGA-mass spectrometry, TGA-infrared spectroscopy, powder X-ray diffraction (XRPD), Karl Fisher titration, high resolution X-ray diffraction, etc. There are several commercial entities that provide rapid and efficient services for routine identification of solvates and hydrates. Example companies that provide these services include Wilmington PharmaTech (Wilmington, Delaware), Avantium Technologies (Amsterdam), and Aptuit (Greenwich, Connecticut).
[0061] The present disclosure includes all isotopes of atoms present in the compounds, salts, solvates and hydrates of the present invention. Isotopes include those atoms with the same atomic number but different mass numbers. One aspect of the present invention includes each combination of one or more atoms in the compounds, salts, solvates and hydrates of the present invention, which are replaced with atoms with the same atomic number but different mass numbers. One such example is to replace the naturally most abundant isotope (e.g. 1 H or 12 C) is replaced by a different atom that is not the most abundant isotope in nature, such as 2 H or 3 H (Replace 1 H), or 11 C. 13 C or 14 C (Replace 12C). When such substitution has occurred, it is generally referred to as isotopically labeled. Isotopic labeling of the compounds, salts, solvates and hydrates of the invention can be accomplished using any of a variety of different synthetic methods known to those of ordinary skill in the art, and who are readily credited with understanding the synthetic methods and available reagents necessary to perform such isotopic labeling. As a general example, but not limited to, isotopes of hydrogen include 2 H (deuterium) and 3 H (tritium). Isotopes of carbon include 11 C. 13 C and 14 C. Nitrogen isotopes include 13 N and 15 N. Isotopes of oxygen include 15 O. 17 O and 18 O. Fluorine isotopes include 18 F. Sulfur isotopes include 35 S. Isotopes of chlorine include 36 Cl. Isotopes of bromine include 75 Br, 76 Br, 77 Br and 82 Br. Iodine isotopes include 123 I. 124 I. 125 I and 131 I. Another aspect of the invention includes compositions, such as those prepared during synthesis, preformulation, etc., and pharmaceutical compositions, such as those intended for use in mammals to treat one or more conditions described herein, comprising one or more compounds, salts, solvates and hydrates of the invention, wherein the naturally occurring distribution of isotopes in the composition is disturbed. Another aspect of the invention includes compositions and pharmaceutical compositions comprising compounds, salts, solvates and hydrates as described herein, wherein the salts are enriched at one or more positions with an isotope other than the naturally most abundant isotope. Methods are readily available for determining such isotopic perturbations or enrichments such as mass spectrometry, and for isotopes of radioactive isotopes, additional methods may be used, such as a radiation detector used in conjunction with HPLC or GC.
[0062] The compounds of the present invention can be converted into "prodrugs". The term "prodrug" means a compound modified with a specific chemical group known in the art, and when administered to an individual, it undergoes a biotransformation to obtain the parent compound. Therefore, a prodrug can be considered a compound of the present invention, which contains one or more specialized non-toxic protective groups used in a transient manner to change or eliminate the properties of the compound. In a general aspect, the "prodrug" method is used to promote oral absorption. In T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems" "American Chemical Society Conference Proceedings (ACS Symposium Series)" Vol. 14; and in "Bioreversible Carriers in Drug Design", Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press, 1987, in-depth discussion, both of which are incorporated herein by reference in their entirety.
[0063] When integers are used in the methods disclosed herein, the term "about" may be inserted before the integer.
[0064] Throughout the specification, unless the context requires otherwise, the word "comprise" or variations such as "comprising", will be understood to imply the inclusion of stated steps or elements or integers or groups of steps or elements or integers but not the exclusion of any other steps or elements or integers or groups of elements or integers.
[0065] Throughout this specification, reference to an individual step, composition of matter, group of steps or group of compositions of matter shall be considered to include both one and multiple (ie, one or more) of those steps, compositions of matter, groups of steps or groups of compositions of matter unless specifically stated otherwise or the context requires otherwise.
[0066] Each embodiment described herein is intended to apply mutatis mutandis to each and every other embodiment unless specifically stated otherwise.
[0067] Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications, except those specifically described. It should be understood that the present invention includes all such variations and modifications. Unless otherwise specifically stated, the present invention also includes all steps, features, compositions and compounds mentioned or indicated in this specification sheet, either individually or in combination, and any and all combinations or any two or more of the steps or features.
[0068] The present invention is not to be limited in scope by the specific embodiments described herein, which are intended for purposes of illustration only. Functionally equivalent products, compositions, and methods are clearly within the scope of the invention as described herein.
[0069] It should be understood that, for the sake of clarity, certain features of the present invention described in the context of separate embodiments may also be provided in combination in a single embodiment. Conversely, for the sake of brevity, various features of the present invention described in the context of a single embodiment may also be provided separately or in any suitable sub-combination. For example, a method of narrating the prescription and / or administration of compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof may be divided into two methods; a method of narrating the prescription of compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof and another method of narrating the administration of compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof. In addition, for example, a method of narrating the prescription of compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof and a separate method of the present invention of narrating the administration of compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof may be combined into a single method of narrating and / or administering compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof.
[0070] Provided herein is a method for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated condition in a subject in need thereof, comprising the steps of: selecting a subject who has not been previously treated with a therapeutically effective amount of an integrin receptor antagonist; and administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0071] Additionally provided is a method of treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated condition in a subject in need thereof, comprising the steps of: selecting a subject who has not been previously treated with an integrin receptor antagonist; and administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0072] Also provided is a method of treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related condition in a subject in need thereof, comprising the steps of: determining whether the subject has been treated with an integrin receptor antagonist; and, if the subject has not been treated with the integrin receptor antagonist, administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopentyl in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1. or a pharmaceutically acceptable salt, solvate or hydrate thereof, or, if the subject has been treated with the integrin receptor antagonist, not administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0073] Also provided is a method for treating sphingosine 1-phosphate subtype 1 (S1P1) receptor-related symptoms in an individual in need thereof, comprising the steps of: selecting an individual who does not suffer from pancolitis; and administering to the individual a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0074] Also provided is a method for treating sphingosine 1-phosphate subtype 1 (S1P1) receptor-related symptoms in an individual in need thereof, comprising the steps of: selecting an individual who does not have a history of pancolitis; and administering to the individual a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0075] Also provided is a method of treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related symptom in a subject in need thereof, comprising the steps of: determining whether the subject has a history of pancolitis; and administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopentadienyl in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1 if the subject does not have a history of pancolitis. [b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof, or, if the individual has a history of pancolitis, not administering a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0076] Additionally provided is a method for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated condition in a subject in need thereof, comprising the steps of: selecting a subject that has been treated with a therapeutically effective amount of an integrin receptor antagonist; and administering to the subject an excess dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
[0077] Further provided herein is a method of treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated condition in a subject in need thereof, comprising the steps of: determining whether the subject has been treated with an integrin receptor antagonist; and administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)- 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof, or, if the subject has been treated with the integrin receptor antagonist, administering to the subject an amount exceeding the standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof.
[0078] Also provided herein is a method of treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated symptom in a subject in need thereof, comprising the steps of: selecting a subject having conjunctivitis or having a history of conjunctivitis; and administering to the subject a dose in excess of a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
[0079] Further provided herein is a method of treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated symptom in a subject in need thereof, comprising the steps of determining whether the subject has colitis or has a history of pancolitis; and administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1 if the subject does not have a history of pancolitis, or administering to the subject a dose greater than the standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof if the subject has a history of pancolitis.
[0080] Further provided herein is a method of treating a subject with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, comprising the steps of: selecting a subject suffering from ulcerative proctitis, proctosigmoiditis, or left-sided colitis; and administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0081] Further provided herein is a method of treating a subject with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof, comprising the steps of: selecting a pharmaceutical composition having at least about 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 80 ... A subject having a baseline lymphocyte count of 825, 850, 875, 900, 925, 950, 975 or 1000 lymphocytes; and administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0082] Further provided herein is a method of treating a sphingosine 1-phosphate isoform 1 (S1P1) receptor-associated condition in a subject in need thereof, comprising the steps of determining whether the subject has at least about 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, or 1000 lymphocytes per microliter. and administering to the subject an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1 if the subject has a baseline lymphocyte count of at least about 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, or 1000 lymphocytes per microliter. A standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof; or wherein the individual does not have at least about 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850 per microliter. In the case of a baseline lymphocyte count of 875, 900, 925, 950, 975 or 100 lymphocytes, the subject is not administered a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0083] Further provided herein is a method of treating a subject with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof, comprising the steps of: selecting a subject that has been exposed to less than or equal to two agents; and administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0084] Also provided is a method of treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related condition in a subject in need thereof, comprising the steps of determining how many biologic agents the subject has been exposed to prior to treatment with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof; and administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1 if the subject has been exposed to less than or equal to two biologic agents. )-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof; or, if the subject has been exposed to more than two biologic agents, not administering a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1 to the subject.
[0085] Also provided herein is a method of treating ulcerative colitis in an individual in need thereof, comprising the steps of: selecting an individual who has not been previously treated with a therapeutically effective amount of vedolizumab; and administering to the individual 2 mg of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
[0086] Also provided is a method of treating ulcerative colitis in an individual in need thereof, comprising the steps of: selecting an individual who has not been previously treated with vedolizumab; and administering to the individual 2 mg of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
[0087] Also provided is a method of treating ulcerative colitis in an individual in need thereof, comprising the steps of determining whether the individual has been treated with vedolizumab; and administering 2 mg of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof to the individual if the individual has not been treated with the integrin receptor antagonist, or not administering (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof to the individual if the individual has been treated with vedolizumab.
[0088] Also provided is a method of treating ulcerative colitis in an individual in need thereof, comprising the steps of: selecting an individual who does not suffer from panconjunctivitis; and administering to the individual 2 mg of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
[0089] Also provided is a method of treating ulcerative colitis in an individual in need thereof, comprising the steps of: selecting an individual who does not have a history of panconjunctivitis; and administering to the individual 2 mg of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
[0090] Also provided is a method of treating ulcerative colitis in an individual in need thereof, comprising the steps of determining whether the individual has a history of panconjunctivitis; and administering 2 mg of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual if the individual does not have a history of panconjunctivitis, or not administering (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual if the individual has a history of panconjunctivitis.
[0091] Also provided is a method for treating ulcerative colitis in an individual in need thereof, comprising the steps of: selecting an individual who has been treated with a therapeutically effective amount of vedolizumab; and administering to the individual greater than 2 mg of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
[0092] Also provided herein is a method of treating ulcerative colitis in an individual in need thereof, comprising the steps of determining whether the individual has been treated with vedolizumab; and administering 2 mg of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof to the individual if the individual has not been treated with vedolizumab, or administering more than 2 mg of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof to the individual if the individual has been treated with vedolizumab.
[0093] Also provided herein is a method of treating ulcerative colitis in an individual in need thereof, comprising the steps of: selecting an individual having panconjunctivitis or having a history of panconjunctivitis; and administering to the individual greater than 2 mg of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
[0094] Also provided herein is a method of treating ulcerative colitis in an individual in need thereof, comprising the steps of determining whether the individual has panconjunctivitis or has a history of panconjunctivitis; and administering to the individual 2 mg of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual does not have a history of panconjunctivitis, or administering to the individual more than 2 mg of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a history of panconjunctivitis.
[0095] In some embodiments, the individual with a history of pancolitis has had pancolitis for about or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 years.
[0096] In some embodiments, the individual with a history of pancolitis has had pancolitis for about or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 years.
[0097] In some embodiments, the individual with a history of pancolitis has had pancolitis for about or greater than about 8 years.
[0098] In some embodiments, the individual with a history of pancolitis has had pancolitis for about or greater than about 8 years.
[0099] In some embodiments, the subject has a baseline lymphocyte count of at least about 800, 825, 850, 875, 900, 925, 950, 975, or 1000 lymphocytes per microliter.
[0100] In some embodiments, the subject has been exposed to less than or equal to one biological agent.
[0101] In some embodiments, the subject has not been exposed to any biological agents.
[0102] In some embodiments, the subject has been exposed to a Janus kinase (JAK) inhibitor approved for the treatment of ulcerative colitis.
[0103] In some embodiments, the biologic agent is selected from golimumab, infliximab, adalimumab, vedolizumab, ustekinumab, and edremazumab.
[0104] In some embodiments, the integrin receptor antagonist is an α4β7 integrin receptor antagonist.
[0105] In some embodiments, the integrin receptor antagonist is vedolizumab.
[0106] In some embodiments, the therapeutically effective amount of vedolizumab is about or at least about 300 mg.
[0107] In some embodiments, the integrin receptor antagonist is natalizumab
[0108] In some embodiments, the therapeutically effective amount of natalizumab is about or at least about 300 mg.
[0109] In some embodiments, the integrin receptor antagonist is edretrinizumab.
[0110] In some embodiments, the integrin receptor antagonist is alirolumab.
[0111] In some embodiments, the integrin receptor antagonist is SHP647.
[0112] In some embodiments, the subject has an inadequate response, loss of response, or intolerance to an integrin receptor antagonist.
[0113] In some embodiments, the subject has an inadequate response, loss of response, or intolerance to vedolizumab.
[0114] In some embodiments, the subject has an inadequate response, loss of response, or intolerance to natalizumab.
[0115] In some embodiments, the individual has demonstrated an inadequate response, loss of response, or intolerance to an integrin receptor antagonist in the past 3 months. In some embodiments, the individual has demonstrated an inadequate response, loss of response, or intolerance to an integrin receptor antagonist in the past 6 months. In some embodiments, the individual has demonstrated an inadequate response, loss of response, or intolerance to an integrin receptor antagonist in the past 9 months. In some embodiments, the individual has demonstrated an inadequate response, loss of response, or intolerance to an integrin receptor antagonist in the past 1 year. In some embodiments, the individual has demonstrated an inadequate response, loss of response, or intolerance to an integrin receptor antagonist in the past 2 years. In some embodiments, the individual has demonstrated an inadequate response, loss of response, or intolerance to an integrin receptor antagonist in the past 3 years. In some embodiments, the individual has demonstrated an inadequate response, loss of response, or intolerance to an integrin receptor antagonist in the past 4 years. In some embodiments, the individual has demonstrated an inadequate response, loss of response, or intolerance to an integrin receptor antagonist in the past 5 years.
[0116] In some embodiments, the individual is selected for treatment based on its baseline lymphocyte count. In some embodiments, the individual is selected for treatment based on the baseline lymphocyte count to increase the possibility of efficacy. In some embodiments, the individual is selected for treatment based on the baseline lymphocyte count to increase the possibility of safety. In some embodiments, the individual has a baseline lymphocyte count of 500-1000 lymphocytes per microliter. In some embodiments, the individual has a baseline lymphocyte count of 400, 450, 500, 550, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975 or 1000 or about at least those lymphocytes per microliter. In some embodiments, the individual has a baseline lymphocyte count of at least 750 lymphocytes per microliter. In some embodiments, the individual has a baseline lymphocyte count of at least 800 lymphocytes per microliter. In some embodiments, the subject has a baseline lymphocyte count of at least 900 lymphocytes per microliter. In some embodiments, the subject has a baseline lymphocyte count of at least 1000 lymphocytes per microliter.
[0117] In some embodiments, an individual is selected for treatment based on the number of biologics to which the individual has been exposed. In some embodiments, the individual selected for treatment has been exposed to ≤1 biologic. In some embodiments, the individual selected for treatment has been exposed to ≤2 biologics. In some embodiments, the individual selected for treatment has not been exposed to ≥1 biologic. In some embodiments, the individual selected for treatment has not been exposed to ≥2 biologics. In some embodiments, the individual selected for treatment has not been exposed to ≥2 biologics plus a Janus kinase (JAK) inhibitor approved for the treatment of ulcerative colitis. In some embodiments, the individual selected for treatment has not been exposed to ≥2 biologics plus a Janus kinase (JAK) inhibitor investigated for the treatment of ulcerative colitis. In some embodiments, the individual selected for treatment has not been exposed to ≥3 biologics.
[0118] In some embodiments, the biologic is a TNFα antagonist. In some embodiments, the biologic is selected from golimumab (SIMPONI), infliximab (REMICADE) and adalimumab (HUMIRA). In some embodiments, the biologic is an integrin receptor antagonist. In some embodiments, the biologic is vedolizumab (ENTYVIO). In some embodiments, the biologic is ustekinumab (STELARA). In some embodiments, the biologic is edrelizumab. In some embodiments, the biologic is a biosimilar of one of the biologics provided herein.
[0119] In some embodiments, the JAK inhibitor is selected from tofacitinib (XELJANZ), filgotinib (Galapagos NV), peficitinib (SMYRAF), upadacitinib (RINVOQ), TD-1473 (Theravance Biopharma), or a combination thereof.
[0120] In some embodiments, treatment comprises inducing and / or maintaining a clinical response; improving the endoscopic appearance of the mucosa; and / or inducing and / or maintaining clinical remission.
[0121] In some embodiments, a standard dose is administered without adjustment.
[0122] In some embodiments, the subject has a 3-point Mayo Clinic score of at least 6 prior to administration.
[0123] In some embodiments, the method results in an improvement in the 3-component Mayo Clinic score of the individual. In some embodiments, the method results in an improvement in the 2-component Mayo Clinic score of the individual. In some embodiments, the method results in an improvement in the total Mayo Clinic score of the individual.
[0124] In some embodiments of the method of treating inflammatory bowel disease, such as ulcerative colitis, such as moderately to severely active ulcerative colitis, the treatment results in endoscopic improvement, such as improvement in the endoscopic appearance of the mucosa.
[0125] In some embodiments of the method of treating inflammatory bowel disease, e.g., ulcerative colitis, such as moderately to severely active ulcerative colitis, treatment induces clinical remission. In some embodiments of the method of treating inflammatory bowel disease, e.g., ulcerative colitis, such as moderately to severely active ulcerative colitis, treatment maintains clinical remission. In some embodiments of the method of treating inflammatory bowel disease, e.g., ulcerative colitis, such as moderately to severely active ulcerative colitis, treatment induces and maintains clinical remission.
[0126] In some embodiments of the method of treating inflammatory bowel disease, e.g., ulcerative colitis, such as moderately to severely active ulcerative colitis, treatment induces a clinical response. In some embodiments of the method of treating inflammatory bowel disease, e.g., ulcerative colitis, such as moderately to severely active ulcerative colitis, treatment maintains a clinical response. In some embodiments of the method of treating inflammatory bowel disease, e.g., ulcerative colitis, such as moderately to severely active ulcerative colitis, treatment induces and maintains a clinical response.
[0127] In some embodiments, treatment reduces lymphocyte counts in the individual by at least 40%. In some embodiments, treatment reduces lymphocyte counts in the individual by at least 45%, 50%, 55%, 60%, or 65%.
[0128] In some embodiments of the method of treating inflammatory bowel disease, such as ulcerative colitis, such as moderately to severely active ulcerative colitis, the treatment results in corticosteroid-free remission.
[0129] In some embodiments of the method of treating inflammatory bowel disease, such as ulcerative colitis, such as moderately to severely active ulcerative colitis, the treatment results in endoscopic remission.
[0130] In some embodiments of the method of treating inflammatory bowel disease, such as ulcerative colitis, such as moderately to severely active ulcerative colitis, treatment results in improvement in rectal bleeding.
[0131] In some embodiments of the method of treating inflammatory bowel disease, such as ulcerative colitis, such as moderately to severely active ulcerative colitis, the treatment results in histological healing.
[0132] In some embodiments of the method of treating inflammatory bowel disease, such as ulcerative colitis, such as moderately to severely active ulcerative colitis, the treatment results in stool frequency.
[0133] In some embodiments of the method of treating inflammatory bowel disease, such as ulcerative colitis, such as moderately to severely active ulcerative colitis, the treatment further comprises monitoring the level of fecal calprotectin.
[0134] In some embodiments of the method of treating inflammatory bowel disease, such as ulcerative colitis, such as moderately to severely active ulcerative colitis, the treatment further comprises monitoring the level of C-reactive protein (CRP).
[0135] In some embodiments, treatment is reduction of signs and / or symptoms of ulcerative colitis. In some embodiments, treatment is reduction of signs of ulcerative colitis. In some embodiments, treatment is reduction of symptoms of ulcerative colitis. In some embodiments, treatment is reduction of signs and / or symptoms of Crohn's disease. In some embodiments, treatment is reduction of signs of Crohn's disease. In some embodiments, treatment is reduction of symptoms of Crohn's disease.
[0136] In some embodiments, treatment is induction and / or maintenance of clinical remission. In some embodiments, treatment is induction and maintenance of clinical remission. In some embodiments, treatment is induction and maintenance of clinical remission and / or clinical response. In some embodiments, treatment is induction and maintenance of clinical remission and / or clinical response. In some embodiments, treatment is induction of clinical remission and / or clinical response. In some embodiments, treatment is maintenance of clinical remission and / or clinical response. In some embodiments, treatment is induction of clinical remission and clinical response. In some embodiments, treatment is maintenance of clinical remission and clinical response. In some embodiments, treatment is induction of clinical remission and clinical response. In some embodiments, treatment is maintenance of clinical remission and clinical response. In some embodiments, treatment is induction and maintenance of clinical remission and / or mucosal healing. In some embodiments, treatment is induction and maintenance of clinical remission and mucosal healing. In some embodiments, treatment is induction and maintenance of mucosal healing. In some embodiments, treatment is induction and maintenance of clinical remission. In some embodiments, treatment is induction of clinical remission. In some embodiments, treatment is induction of mucosal healing. In some embodiments, treatment is maintenance of clinical remission. In some embodiments, treatment is maintenance of mucosal healing. In some embodiments, treatment is to achieve and / or maintain clinical remission in induction responders. In some embodiments, treatment is to achieve and maintain clinical remission in induction responders. In some embodiments, treatment is to achieve clinical remission in induction responders. In some embodiments, treatment is to maintain clinical remission in induction responders. In some embodiments, the treatment is to induce and / or maintain a clinical response. In some embodiments, the treatment is to induce and maintain a clinical response. In some embodiments, the treatment is to induce a clinical response. In some embodiments, the treatment is to maintain a clinical response. In some embodiments, the treatment is to induce endoscopic improvement. In some embodiments, the treatment is to maintain endoscopic improvement. In some embodiments, the treatment is to achieve endoscopic improvement. In some embodiments, the treatment is to improve endoscopic remission. In some embodiments, the treatment is to maintain endoscopic remission. In some embodiments, the treatment is to induce histological healing. In some embodiments, the treatment is to maintain histological healing. In some embodiments, the treatment is to improve stool frequency. In some embodiments, the treatment is to maintain improvement in stool frequency. In some embodiments, the treatment is to improve the endoscopic appearance of the mucosa. In some embodiments, the treatment is to maintain endoscopic improvement of the mucosa. In some embodiments, the treatment is to improve the endoscopic appearance of the mucosa during induction. In some embodiments, the treatment eliminates the need for corticosteroid use. In some embodiments, the treatment allows for reduced use of corticosteroids. In some embodiments, the treatment allows for the use of lower doses of corticosteroids. In some embodiments, the treatment is to achieve remission without corticosteroids. In some embodiments, the treatment is to maintain remission without corticosteroids. In some embodiments, the treatment is to improve rectal bleeding. In some embodiments, the treatment is to maintain the improvement in rectal bleeding. In some embodiments, the treatment is to improve the endoscopy subscore. In some embodiments, the treatment is to maintain the improvement in the endoscopy subscore.
[0137] In some embodiments, the subject has a 3-point Mayo Clinic score of at least 6 prior to said administering.
[0138] In some embodiments, the administration results in an improvement in the subject's 3-point Mayo Clinic score.
[0139] In some embodiments, the administration results in an improvement in the subject's 2-point Mayo Clinic score.
[0140] In some embodiments, the administration results in an improvement in the subject's total Mayo Clinic score.
[0141] In some embodiments, the administration results in an improvement in the endoscopic appearance of a mucosa of the subject.
[0142] In some embodiments, said administration results in inducing clinical remission in the individual.
[0143] In some embodiments, said administration results in maintenance of clinical remission in the individual.
[0144] In some embodiments, said administration results in inducing and maintaining clinical remission in the individual.
[0145] In some embodiments, said administration results in inducing a clinical response in the individual.
[0146] In some embodiments, said administration results in maintenance of a clinical response in the individual.
[0147] In some embodiments, said administration results in inducing and maintaining a clinical response in the individual.
[0148] In some embodiments, a 2-component Mayo Clinic score has been used to diagnose ulcerative colitis. For example, in some embodiments, a score of rectal bleeding and endoscopic findings ranging from 0 to 9 has been used to diagnose ulcerative colitis. In some embodiments, a 3-component Mayo Clinic score has been used to diagnose ulcerative colitis. For example, in some embodiments, a score of stool frequency, rectal bleeding, and endoscopic findings ranging from 0 to 9 has been used to diagnose ulcerative colitis. In some embodiments, a total Mayo score has been used to diagnose ulcerative colitis. For example, in some embodiments, a score of stool frequency, rectal bleeding, endoscopic findings, and a physician's overall assessment ranging from 0 to 12 has been used to diagnose ulcerative colitis.
[0149] In some embodiments, the improvement of ulcerative colitis is measured using a 2-component Mayo Clinic score. In some embodiments, the improvement of ulcerative colitis is measured using a 3-component Mayo Clinic score. In some embodiments, the improvement of ulcerative colitis is measured using a total Mayo score. In some embodiments, the improvement of ulcerative colitis is measured by clinical remission. In some embodiments, the improvement of ulcerative colitis is measured by lymphopenia. In some embodiments, the improvement of ulcerative colitis is measured by endoscopic improvement. In some embodiments, the improvement of ulcerative colitis is measured by a 6-point Mayo score. For example, in some embodiments, the improvement of ulcerative colitis is measured by stool frequency and rectal bleeding. In some embodiments, the improvement of ulcerative colitis is statistically significant.
[0150] In some embodiments, the subject responds inadequately, loses response, is intolerant, or exhibits dependence to an integrin receptor antagonist for treating inflammatory bowel disease. In some embodiments, the subject responds inadequately to an integrin receptor antagonist for treating inflammatory bowel disease. In some embodiments, the subject loses response to an integrin receptor antagonist for treating inflammatory bowel disease. In some embodiments, the subject is intolerant to an integrin receptor antagonist for treating inflammatory bowel disease.
[0151] In some embodiments, the S1P1 receptor-associated disorder is a disease or disorder mediated by lymphocytes.
[0152] In some embodiments, the S1P1 receptor-associated disorder is an autoimmune disease or disorder.
[0153] In some embodiments, the S1P1 receptor-associated disorder is an inflammatory disease or disorder.
[0154] In some embodiments, the S1P1 receptor-associated disorder is ulcerative colitis.
[0155] In some embodiments, the S1P1 receptor-associated disorder is selected from one or more of the following: ulcerative proctitis, proctosigmoiditis, and left-sided colitis.
[0156] In some embodiments, the S1P1 receptor-associated disorder is proctitis.
[0157] In some embodiments, the S1P1 receptor-associated disorder is ulcerative proctitis.
[0158] In some embodiments, the S1P1 receptor-associated disorder is proctosigmoiditis.
[0159] In some embodiments, the S1P1 receptor-associated disorder is left-sided colitis.
[0160] In some embodiments, the S1P1 receptor-associated disorder is Crohn's disease.
[0161] In some embodiments, the S1P1 receptor-associated disorder is inflammatory bowel disease (IBD).
[0162] In some embodiments, the S1P1 receptor-associated disorder is an active cutaneous extraintestinal manifestation of inflammatory bowel disease. In some embodiments, the S1P1 receptor-associated disorder is an active cutaneous extraintestinal manifestation of ulcerative colitis. In some embodiments, the active cutaneous extraintestinal manifestation is psoriasis. In some embodiments, the active cutaneous extraintestinal manifestation is erythema nodosum. In some embodiments, the active cutaneous extraintestinal manifestation is pyoderma gangrenosum.
[0163] In some embodiments, the S1P1 receptor-associated disorder is ulcerative colitis. In some embodiments, the S1P1 receptor-associated disorder is moderately to severely active ulcerative colitis. In some embodiments, the S1P1 receptor-associated disorder is moderately active ulcerative colitis. In some embodiments, the S1P1 receptor-associated disorder is severely active ulcerative colitis. In some embodiments, the S1P1 receptor-associated disorder is mildly to moderately active ulcerative colitis. In some embodiments, the S1P1 receptor-associated disorder is mildly active ulcerative colitis.
[0164] In some embodiments, not administering a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof to a subject is administering a dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof to a subject that exceeds a standard dose.
[0165] In some embodiments, not administering a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof to a subject is not administering (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof to a subject.
[0166] In some embodiments, the standard dose amount is equivalent to 1 mg of Compound 1.
[0167] In some embodiments, standard dose amounts are equivalent to 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, and 3 mg of Compound 1, or about those amounts of the compound.
[0168] In some embodiments, the standard dose amount is equivalent to 1.5 mg of Compound 1.
[0169] In some embodiments, the standard dose amount is equivalent to 2 mg of Compound 1.
[0170] In some embodiments, the standard dose amount is equivalent to 2.5 mg of Compound 1.
[0171] In some embodiments, the standard dose amount is equivalent to 3 mg of Compound 1.
[0172] In some embodiments, a standard dose of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is administered to a subject once daily.
[0173] In some embodiments, Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is administered orally.
[0174] In some embodiments, Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is formulated as capsules or tablets suitable for oral administration.
[0175] In some embodiments, Compound 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof is selected from: Compound 1; a calcium salt of Compound 1; and an L-arginine salt of Compound 1. In some embodiments, Compound 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof is an L-arginine salt of Compound 1. In some embodiments, Compound 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof is an anhydrous, non-solvated crystalline form of an L-arginine salt of Compound 1. In some embodiments, Compound 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof is an anhydrous, non-solvated crystalline form of Compound 1.
[0176] Also provided are pharmaceutical compositions comprising a standard dose of Compound 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof and optionally one or more pharmaceutically acceptable carriers. Also provided are pharmaceutical compositions comprising Compound 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof, optionally one or more pharmaceutically acceptable carriers. The carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
[0177] In some embodiments, Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is administered as a crude or pure chemical (eg, as a powder in a capsule formulation).
[0178] In some embodiments, Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is formulated as a pharmaceutical composition further comprising one or more pharmaceutically acceptable carriers.
[0179] The pharmaceutical compositions may be prepared by any suitable method, generally by uniformly admixing the active compound with liquid or finely divided solid carriers or both in the required proportions and then, if necessary, shaping the resulting mixture into the desired presentation.
[0180] Conventional excipients, such as binders, fillers, acceptable wetting agents, tableting lubricants and disintegrants can be used in tablets and capsules for oral administration. The compounds described herein can be formulated into pharmaceutical compositions using techniques well known to those skilled in the art. In addition to those mentioned herein, suitable pharmaceutically acceptable carriers are known in the art; for example, see Remington, The Science and Practice of Pharmacy, 20th edition, 2000, Lippincott Williams & Wilkins, (Editors: Gennaro et al.).
[0181] For oral administration, the pharmaceutical composition may be in the form of, for example, tablets or capsules. The pharmaceutical composition is preferably prepared in the form of a dosage unit containing a specific amount of active ingredient. Examples of such dosage units are capsules, tablets, powders, granules or suspensions with conventional additives such as lactose, mannitol, corn starch or potato starch; with binders such as crystalline cellulose, cellulose derivatives, gum arabic, corn starch or gelatin; with disintegrants such as corn starch, potato starch or sodium carboxymethyl cellulose; and with lubricants such as talc or magnesium stearate. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories and dispersible granules. A solid carrier may be one or more substances, which may also act as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, preservative, tablet disintegrant or encapsulating material.
[0182] In powders, the carrier is a finely divided solid, which is in admixture with the finely divided active component.
[0183] In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
[0184] Powders and tablets may contain varying percentage amounts of active compound. A representative amount in a powder or tablet may be from 0.5% to about 90% of the active compound. However, a skilled person will know when amounts outside this range are required. Suitable carriers for powders and tablets include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low melting waxes, cocoa butter, and the like. The term "preparation" includes formulations of active compounds with encapsulating materials as carriers providing capsules, wherein the active component with or without a carrier is surrounded by a carrier, which is thus combined with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
[0185] The pharmaceutical preparation is preferably in unit dosage form. In this form, the preparation is subdivided into unit doses containing appropriate amounts of active ingredients. The unit dosage form may be a packaged preparation containing discrete amounts of the preparation, such as packaged tablets or capsules. In addition, the unit dosage form may be a capsule or tablet itself, or it may be any of these in an appropriate number of packaged forms.
[0186] Other embodiments include those disclosed in the following examples, which should not be construed as limiting in any way.
[0187] Examples
[0188] Example 1
[0189] As shown in Table 1, formulations consisting of immediate release hard gelatin capsules containing the L-arginine salt of Compound 1 were prepared.
[0190] Table 1
[0191]
[0192]
[0193] * Approximate weight. Based on capsule size
[0194] ** Theoretical total weight calculated by combining the filled and empty capsule weights
[0195] As shown in Table 2, a placebo formulation consisting of a hard gelatin capsule containing microcrystalline cellulose was also prepared.
[0196] Table 2
[0197]
[0198] * Approximate weight ±15%
[0199] ** Approximate weight. Based on capsule size
[0200] *** Theoretical total weight calculated by combining the filled and empty capsule weights
[0201] Example 2
[0202] A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study was conducted to evaluate the safety and efficacy of two orally administered doses (1 mg and 2 mg) of Compound 1 in patients with ulcerative colitis. The following table provides a summary of demographic data by treatment group.
[0203]
[0204]
[0205]
[0206] Patients were randomized into a double-blind, placebo-controlled study to receive once daily (qd) doses of L-arginine salt of Compound 1 (1 mg or 2 mg) or matching placebo for 12 weeks in a 1:1:1 ratio. The trial enrolled 156 patients with moderate to severe ulcerative colitis (3-point Mayo score of 4-9, including an endoscopic subscore ≥2 and a rectal bleeding score ≥1).
[0207] The treatment formulation consisted of immediate release hard gelatin capsules containing the L-arginine salt of Compound 1. The placebo consisted of hard gelatin capsules containing microcrystalline cellulose.
[0208] The patient has demonstrated an inadequate response to, loss of response to, or intolerance to at least one of the following agents during the past 5 years:
[0209] Oral 5-aminosalicylic acid (5-ASA) (eg, mesalamine);
[0210] Corticosteroids, where the patient shows signs and symptoms of persistent active disease despite a history of at least one 4-week induction regimen that included a dose equivalent to prednisone 30 mg per day; or 2 failed attempts to taper corticosteroids to less than the equivalent of prednisone 10 mg per day; or a history of corticosteroid intolerance (including but not limited to Cushing's syndrome, osteopenia / osteoporosis, hyperglycemia, insomnia, and infection);
[0211] Immunosuppressants where the patient shows signs and symptoms of persistent active disease despite a history of at least one 8-week regimen of oral azathioprine (≥1.5 mg / kg) or 6-mercaptopurine (≥0.75 mg / kg); or a history of intolerance to at least one of these immunosuppressants (including but not limited to nausea / vomiting, abdominal pain, pancreatitis, LFT abnormalities, lymphocytopenia, TPMT gene mutation, infection); or
[0212] TNFα antagonist, where the patient exhibits signs and symptoms of persistent active disease regardless of a history of completing an induction regimen with at least one of the following: infliximab, adalimumab, or golimumab at a dose in accordance with current labeling and / or institutional standards; or symptoms recur during maintenance dosing with infliximab, adalimumab, or golimumab after prior clinical benefit (without interruption granted regardless of clinical benefit); or history of intolerance to infliximab, adalimumab, or golimumab (including, but not limited to, infusion- or injection-related reactions, demyelination, congestive heart failure, infection); or
[0213] Integrin antagonists, in which patients show recurrence of symptoms during maintenance dosing with vetalizumab after prior clinical benefit (interruptions are granted regardless of clinical benefit); or a history of intolerance to vetalizumab (including but not limited to infusion-related reactions).
[0214] Patients were instructed to take their capsules on an empty stomach (approximately 8 hours overnight fast) and to avoid eating within approximately 1 hour after dosing.
[0215] The primary objective of this proof-of-concept study was to determine the effect of treatment with the L-arginine salt of Compound 1 on change in the 3-point Mayo Clinic score (a score ranging from 0 to 9 that includes stool frequency, rectal bleeding, and endoscopic findings) at 12 weeks.
[0216] Secondary end points were the proportion of patients achieving endoscopic improvement at week 12; change in the 2-component Mayo score at week 12 (a score ranging from 0 to 6 that includes rectal bleeding and endoscopic findings); and change in the total Mayo score at week 12 (a score ranging from 0 to 12 that includes stool frequency, rectal bleeding, endoscopic findings, and physician global assessment).
[0217] Exploratory endpoints included change from baseline in lymphocyte counts at weeks 1, 2, 4, 8, and 12; the proportion of patients achieving clinical remission at week 12; and the proportion of patients achieving clinical response at week 12.
[0218] ANCOVA models adjusted for current oral glucocorticoid use, prior exposure to TNF-α antagonists, and baseline values were used to estimate changes in Mayo Clinic scores. The Mantel-Haenszel method (estimating treatment differences by adjusting current oral corticosteroid use and prior exposure to TNF-α antagonists) was used to estimate proportion differences for dichotomous parameters. Individual Mayo subscores that lacked effects on efficacy measures were imputed using multiple imputation methodology together with case analyses observed for sensitivity. Statistical tests were pre-specified as one-sided, with p<0.025 reflecting conventional statistical significance. A hierarchical closed trial procedure for primary and secondary endpoints at the 0.05α level was used.
[0219] Patients receiving the high dose (2 mg) of the L-arginine salt of Compound 1 achieved the primary and all secondary endpoints with statistical significance.
[0220] Relative to placebo, there was a 0.99 improvement in the 3-point partial Mayo score (PMS; a score ranging from 0 to 9, including stool frequency, rectal bleeding, and endoscopic findings) with the L-arginine salt of Compound 1 at 2 mg at week 12, which was statistically significant (p=0.009). In the low-dose (1 mg) group, there was a 0.43 improvement in PMS at week 12 relative to placebo, which was not statistically significant (p=0.146).
[0221] Significantly more patients in the L-arginine salt of Compound 1 (2 mg) group achieved endoscopic improvement compared to placebo (41.8% vs. 17.8%, p=0.003). For the 1 mg group, 22.5% of patients achieved endoscopic improvement (p=0.306).
[0222] There was a 0.84 improvement in the 2-component Mayo score (a score ranging from 0 to 6 that includes rectal bleeding and endoscopic findings) at Week 12 relative to placebo, which was statistically significant (p=0.002). In the low-dose (1 mg) group, there was a 0.39 improvement relative to placebo, which was not statistically significant (p=0.086).
[0223] There was a 1.27 improvement in the total Mayo score (a score ranging from 0 to 12 that includes stool frequency, rectal bleeding, endoscopic findings, and physician global assessment) for the 2 mg group at week 12 relative to placebo (p=0.010). In the low dose (1 mg) group, there was a 0.60 improvement relative to placebo, which was not statistically significant (p=0.128).
[0224] In an exploratory analysis, the proportion of patients achieving clinical remission as defined by the 3-point Mayo score was 33.0% in the L-arginine salt of Compound 1 (2 mg) group compared to 8.1% in the placebo group (p<0.001). For the 1 mg group, 16.0% of patients achieved clinical remission (p=0.136)
[0225] Remission, as defined by the 4-point total Mayo score, was 24.5% and 6.0% for the L-arginine salt of Compound 1 and placebo, respectively (p=0.004). Remission in the 1 mg group was 15.4% (p=0.077).
[0226] Relative to placebo, at 12 weeks there was a 57% decrease in lymphocytes for the 2 mg group (p<0.001) while there was a 37% decrease for the 1 mg group.
[0227] Figure 1 Shown is a comparison of the percentage of patients with endoscopic improvement for various treatments for ulcerative colitis. Figure 2 Shown is a comparison of the percentage of patients in clinical remission, defined as the total Mayo score, for various treatments for ulcerative colitis < Proportion of patients with a score of 2 and no subscore >1 (responses varied across studies and comparisons are not made from direct head-to-head studies).
[0228] Overall, the results of prespecified subgroup analyses of improvement in modified MCS, including baseline disease characteristics and current and previous treatments, were similar to those of the primary analysis. The exceptions were prior use of vedolizumab and a history of pancolitis ( Figures 3A-3D ).
[0229] The L-arginine salt of Compound 1 was well tolerated and had fewer serious adverse events (SAEs) than placebo (0% in 2 mg; 5.8% in 1 mg; and 11.1% in placebo).
[0230]
[0231] Effects on heart rate and AV conduction were low throughout the study period, with no study discontinuations related to bradycardia or AV block. There were no increases in liver function tests (LFTs) compared to placebo and no reports of macular edema or abnormal pulmonary function tests.
[0232] Regarding possible cardiac events, hourly ECGs on day 1 in both the 1 mg and 2 mg groups showed a mild decrease in heart rate, with the mean rate change in either group at any time point being >10 bpm. After Day 1, the mean heart rate decrease from baseline did not exceed 6 bpm in any dose group throughout Week 12. No serious adverse events related to heart rate changes or atrioventricular block were recorded.
[0233] There were no increases in liver function tests compared to placebo; no reports of macular edema; and no reports of abnormal lung function tests.
[0234] The researchers rated adverse events among infections and infestations as mild or moderate. No serious or life-threatening infections occurred. Most adverse events were upper respiratory tract infections.
[0235] Example 3:
[0236] A randomized, double-blind, placebo-controlled 12-week study will be conducted to evaluate the safety and efficacy of compound 1 (2 mg) or placebo in patients with moderately to severely active ulcerative colitis (UC). The efficacy of compound 1 on clinical remission, clinical response, symptom response and remission, endoscopic changes, and mucosal healing will be evaluated at 12 weeks of administration. Other objectives include evaluating compound 1 pharmacokinetics (PK) and the effects of compound 1 on health-related subject-reported outcomes and biomarkers.
[0237] Inclusion criteria will include the following:
[0238] 1. Male or female aged 16 to 80 years (inclusive)
[0239] 2. Ability to provide written informed consent or assent (parents or legal guardians must provide assent for subjects who have agreed to participate in the study or who are younger than 18 years of age as required by local regulations) and to adhere to the schedule of protocol assessments
[0240] 3. Diagnosed with UC ≥3 months prior to screening. The diagnosis of UC will be confirmed by endoscopic and histological evidence.
[0241] 4. Active UC confirmed by endoscopy with ≥10 cm rectal involvement. Enrollment of subjects with proctitis at baseline only will be capped at 15% of total subjects enrolled.
[0242] 5. Moderately to severely active UC defined as modified Mayo score (MMS) 4 to 9 (including endoscopic score (ES) ≥2 and rectal bleeding (RB) score ≥1).
[0243] 6. Underwent surveillance colonoscopy within 12 months prior to baseline to exclude dysplasia in subjects with pancolitis >8 years duration or subjects with left-sided colitis >12 years duration. Subjects who have not had a colonoscopy within the prior 12 months will have a colonoscopy at screening (i.e., in lieu of a screening proctosigmoidoscopy). Any adenomatous polyps will be removed prior to the first dose of study treatment.
[0244] 7. Demonstrated inadequate response, loss of response, or intolerance to at least one of the following therapies as defined below:
[0245] Conventional treatments:
[0246] a. Oral administration of 5-aminosalicylic acid (5ASA) compounds
[0247] b. Corticosteroids
[0248] c. Thiopurine
[0249] Biological therapy or JAK inhibitor therapy:
[0250] a. Anti-tumor necrosis factor alpha (TNFα) antibodies (eg, infliximab, adalimumab, golimumab, or biosimilars)
[0251] b. Anti-integrin antibodies (eg, vedolizumab)
[0252] c.JAK inhibitors (eg, tofacitinib)
[0253] 8. Subjects are allowed to receive therapeutic doses of the following drugs:
[0254] Oral 5ASA compound, provided the dose was stable for ≥2 weeks immediately before randomization
[0255] Oral corticosteroid therapy (stable dose of prednisone ≤ 20 mg / day, stable dose of budesonide ≤ 9 mg / day or equivalent steroid) if dose is stable within 4 weeks immediately prior to screening endoscopic evaluation
[0256] Immunosuppressants such as oral azathioprine or 6-mercaptopurine must be discontinued ≥ 2 weeks prior to randomization
[0257] Probiotics (e.g. Saccharomyces boulardii), provided that the dose was stable within 2 weeks immediately prior to randomization
[0258] Antidiarrheal drugs for the control of chronic diarrhea (for example, loperamide, diphenoxylate, and atropine)
[0259] If oral aminosalicylates or corticosteroids have been recently discontinued, they must be discontinued for at least 2 weeks prior to endoscopy for baseline MMS.
[0260] 9. Vital signs at screening and pre-randomization in a sitting position: heart rate ≥50 bpm, systolic blood pressure (BP) ≥90 mm Hg, and diastolic BP ≥55 mm Hg
[0261] 10. Screening and pre-randomization 12-lead electrocardiogram (ECG) showing no clinically significant abnormalities with PR interval ≤ 200 ms, Fridericia-corrected QT interval (QTcF) < 450 ms (males) or QTcF < 470 ms (females)
[0262] 11. Adequate hematologic function defined by a white blood cell count ≥3.5×109 / L with an absolute neutrophil count ≥1.5×109 / L, a lymphocyte count ≥0.8×109 / L, a platelet count ≥100×109 / L, and hemoglobin ≥8g / dL
[0263] 12. Adequate liver function defined by total bilirubin levels ≤1.5× upper limit of normal (ULN) range and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤3.0×ULN. Subjects diagnosed with Gilbert's syndrome with isolated total bilirubin and normal AST and ALT may participate
[0264] 13. Adequate renal function defined by estimated glomerular filtration rate ≥ 30 mL / min / 1.73 m2 at screening via the CKD-EPI equation
[0265] 14. Women of childbearing age who are capable of giving birth must be:
[0266] a. Not pregnant
[0267] b. Not breastfeeding
[0268] 15. Both male and female subjects agree to use highly effective birth control methods throughout the study
[0269] Exclusion criteria will include the following:
[0270] 1. Severe extensive colitis as evidenced by:
[0271] The subject is judged by the physician to be likely to require hospitalization or any type of surgical intervention for UC (e.g., colectomy) within 12 weeks of baseline
[0272] Fulminant colitis, toxic megacolon, or recent history (within the past 6 months) or current evidence of intestinal perforation
[0273] Previous total or partial colectomy
[0274] 2. Diagnosis of Crohn's disease or indeterminate colitis or the presence or history of fistulas consistent with Crohn's disease
[0275] 3. Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis
[0276] 4. Hospitalization for UC exacerbation requiring intravenous (IV) steroids within 12 weeks of screening (single dose of IV steroids is acceptable)
[0277] 5. Positive laboratory test or stool culture for pathogens or positive test for Clostridium difficile toxin at screening
[0278] 6. Pregnancy, lactation, or positive serum βhCG measured during the screening period
[0279] 7. Clinically relevant hematologic, hepatic, neurological, pulmonary, ophthalmic, endocrine, metabolic, psychiatric, or other major systemic disease that would make implementation of the study protocol or interpretation difficult or would place subjects at risk
[0280] 8. Recent history of cardiovascular disease including myocardial infarction or unstable angina (within 2 months of the screening visit)
[0281] 9. History of any of the following, unless treated with an implantable pacemaker or implantable cardioverter-defibrillator in conjunction with pacing:
[0282] History or presence of symptomatic bradycardia
[0283] History of sick sinus syndrome or neurocardiogenic syncope
[0284] Second or third degree atrioventricular block
[0285] Cardiac arrest duration > 3 seconds
[0286] 10. Forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC) < 70% of predicted value and FEV1 / FVC ratio < 0.70 at screening
[0287] 11. Uncontrolled diabetes as determined by hemoglobin A1c (HbA1c) > 9% at screening, or subjects with diabetes with significant complications such as retinopathy
[0288] 12. History of macular edema or retinal disease
[0289] 13. Current or past history of active tuberculosis (TB), history of untreated latent TB infection, or positive test for latent TB infection at screening.
[0290] 14. Known active bacterial, viral, fungal, mycobacterial infection, or other infection requiring hospitalization or treatment with IV antibiotics within 30 days of screening or during the screening period or oral antibiotics within 14 days prior to screening or any significant episode of infection. Fungal infection of the nail bed is permitted
[0291] 15. Having HIV / acquired immunodeficiency syndrome or HIV antibody positive at screening
[0292] 16. Having acute or chronic hepatitis B infection or testing positive for hepatitis B virus (HBV) at screening
[0293] 17. Hepatitis C infection or positive hepatitis C virus (HCV) test at screening as defined by positive hepatitis C antibodies and detectable HCV RNA
[0294] 18. History of opportunistic infection (e.g., Pneumocystis carinii, cryptococcal meningitis, progressive multifocal leukoencephalopathy) or serious bacterial, viral, or fungal infection (e.g., disseminated herpes simplex, disseminated herpes zoster) requiring IV medication for ≤ 3 weeks prior to randomization
[0295] 19. History of current active primary or secondary immunodeficiency
[0296] 20. History of cancer within the past five years, including solid tumors and hematologic malignancies (except for resected and cured basal cell carcinoma of the skin and squamous cell carcinoma in situ) or colon mucosal dysplasia
[0297] 21. History of lymphoproliferative disease, lymphoma, leukemia, myeloproliferative disease, or multiple myeloma
[0298] 22. History of alcohol or drug abuse within one year before randomization
[0299] 23. Prior treatment with sphingosine 1-phosphate receptor modulators
[0300] 24. Treatment with biologic agents within 8 weeks or five elimination half-lives (whichever is shorter)
[0301] 25. Treatment with investigational therapy within three months prior to randomization
[0302] 26. Treatment failure on ≥3 biologics or ≥2 biologics plus a JAK inhibitor approved for the treatment of UC
[0303] 27. Treatment with topical rectal 5ASA, short-chain fatty acid enemas, or steroid therapy within two weeks of screening or during the screening period
[0304] 28. Treatment with cyclosporine, tacrolimus, sirolimus, methotrexate, or mycophenolate mofetil within 16 weeks of screening
[0305] 29. Received a live vaccine within 4 weeks prior to randomization
[0306] 30. Previous treatment with natalizumab
[0307] 31. Previous treatment with lymphocyte depletion therapy
[0308] 32. Previous treatment with D-penicillamine, leflunomide, or thalidomide
[0309] 33. Treatment with IV immunoglobulin or plasma exchange within three months before randomization
[0310] 34. Chronic use of therapy that moderately / strongly inhibits / induces cytochrome P450 (CYP) 2C8 and 2C9 metabolism and UGT1A7 inhibitors within 4 weeks prior to randomization
[0311] Efficacy endpoints will evaluate Compound 1 relative to placebo in terms of:
[0312] Proportion of subjects in clinical remission at Week 12
[0313] Proportion of subjects achieving endoscopic improvement at Week 12
[0314] Proportion of subjects with mucosal healing at Week 12
[0315] Proportion of subjects with clinical response at Week 12
[0316] Proportion of subjects with endoscopic improvement at Week 12
[0317] Proportion of subjects with endoscopic normalization at Week 12
[0318] Proportion of subjects with clinical response for RB and SF symptom outcomes at each of the following time points: Weeks 2, 4, 8, and 12
[0319] Proportion of subjects with clinical remission for RB and SF symptom outcomes at each of the following time points: Weeks 2, 4, 8, and 12
[0320] Proportion of subjects with remission and response using total Mayo Clinic score at Week 12
[0321] Proportion of subjects with histologic response at Week 12 (as defined by the Geboes, Robarts, and Nancy histopathology score)
[0322] Proportion of subjects with histological improvement at Week 12 (as defined by Geboes, Robarts, and Nancy histopathology score)
[0323] Proportion of subjects with improvement in extraintestinal manifestations (EIM) at Week 12 compared with subjects with EIM at baseline
[0324] The following scores and changes from baseline to Week 12:
[0325] - Inflammatory Bowel Disease Questionnaire (IBDQ) total score
[0326] - Ulcerative Colitis Patient-Reported Outcomes Signs and Symptoms (UC-PRO-SS)
[0327] -Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) Version 2, physical and mental subscale and domain scores
[0328] - Work Productivity and Activity Impairment Inventory-Ulcerative Colitis (WPAI-UC)
[0329] - Numerical Rating Scale (NRS)
[0330] - Abdominal pain NRS
[0331] Proportion of UC-related hospitalizations
[0332] Proportion of subjects requiring UC-related surgery, including colectomy
[0333] Plasma concentrations of Compound 1, M3, and other metabolites of interest (if indicated) will be determined based on samples collected prior to and 4 hours (±15 minutes) after dosing (following a 12-lead ECG) at Week 0 / Day 1
[0334] Plasma concentrations of Compound 1, M3, and other metabolites of interest (if necessary) will be determined based on samples collected prior to dosing at Weeks 2, 4, 8, and 12
[0335] Change from baseline in fecal calprotectin levels at Weeks 4, 8, and 12.
[0336] Change from baseline in high-sensitivity C-reactive protein (hs-CRP) levels at weeks 2, 4, 8, and 12
[0337] Change from baseline in lymphocyte counts at weeks 2, 4, 8, and 12.
[0338] The incidence and severity of adverse events
[0339] The incidence and severity of laboratory abnormalities and changes from baseline in laboratory values (including hematology, serum chemistry, coagulation, and urinalysis)
[0340] The incidence and changes from baseline in clinically significant vital sign abnormalities
[0341] Evaluations will be performed at Weeks 2, 4, 8, and 12. Eligible participants will be given the opportunity to enter an open-label extension (OLE) of Compound 1.
[0342] Example 4
[0343] A randomized, double-blind, placebo-controlled 52-week study will be conducted to evaluate the safety and efficacy of Compound 1 (2 mg) or placebo in patients with moderately to severely active ulcerative colitis (UC). The efficacy of Compound 1 on clinical remission, clinical response, symptom response and remission, endoscopic changes, and mucosal healing will be evaluated at 52 weeks of administration. Other objectives include evaluating Compound 1 pharmacokinetics (PK) and the effects of Compound 1 on health-related subject-reported outcomes and biomarkers.
[0344] Inclusion and exclusion criteria will be similar to those described in Example 3.
[0345] Efficacy endpoints will evaluate Compound 1 relative to placebo in terms of:
[0346] Proportion of subjects achieving endoscopic improvement at Week 52
[0347] Proportion of subjects achieving endoscopic improvement at Week 12
[0348] Proportion of subjects who had not received corticosteroids for ≥12 weeks prior to the end of the study (Week 52) and who were in clinical remission at Week 52
[0349] Proportion of subjects with mucosal healing at Week 52
[0350] Proportion of subjects with mucosal healing at Week 12
[0351] Proportion of subjects achieving clinical remission at Week 12 and Week 52
[0352] Proportion of subjects with clinical response at Week 52
[0353] Proportion of subjects with clinical response at Week 12
[0354] Proportion of subjects with endoscopic normalization at Week 52
[0355] Proportion of subjects with endoscopic normalization at Week 12
[0356] Proportion of subjects with symptom relief at Week 52
[0357] Proportion of subjects with symptom relief at Week 12
[0358] Proportion of subjects with non-invasive clinical response at Weeks 12, 16, 20, 24, 32, 40, 48, and 52
[0359] Proportion of subjects with symptomatic response at Weeks 12, 16, 20, 24, 32, 40, 48, and 52
[0360] Proportion of subjects in remission at Week 52 and free of corticosteroids since Weeks 16, 24, 32, 40, and 48
[0361] Proportion of subjects with clinical response at Week 12 who were in clinical remission at Week 52
[0362] Proportion of subjects achieving clinical response at Week 12 and Week 52
[0363] Proportion of subjects achieving mucosal healing at Week 12 and Week 52
[0364] Proportion of subjects achieving endoscopic normalization at Week 12 and Week 52
[0365] Proportion of subjects with clinical response for RB and SF symptom outcomes at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52
[0366] Proportion of subjects with clinical remission for RB and SF symptom outcomes at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52
[0367] Proportion of subjects with remission and response using total Mayo Clinic score at Week 12
[0368] Proportion of subjects with remission and response using total Mayo Clinic score at Week 52
[0369] Proportion of subjects with histological improvement at Week 12 (as defined by Geboes, Robarts, and Nancy histopathology score)
[0370] Proportion of subjects with histologic improvement at Week 52 (as defined by Geboes, Robarts, and Nancy histopathology scores)
[0371] Proportion of subjects with histologic response at Week 12 (as defined by the Geboes, Robarts, and Nancy histopathology score)
[0372] Proportion of subjects with histologic response at Week 52 (as defined by the Geboes, Robarts, and Nancy histopathology score)
[0373] Loss of reaction time, where loss of reaction is defined by:
[0374] - A ≥2-point increase in combined SF+RB score of ≥4 and combined SF+RB score from Week 12 at 2 consecutive visits (≥7 days apart), and
[0375] - confirmed by centralized reading ES ≥ 2, and
[0376] -Confirmation of negative C. difficile test
[0377] Proportion of subjects with EIMs at baseline who had improvements in EIMs at Week 12 and Week 52
[0378] The following scores and changes from baseline at Week 12 and Week 52:
[0379] -IBDQ overall score
[0380] -UC-PRO / SS
[0381] -SF-36, Version 2, Physical and Mental Components and Domain Scores
[0382] -WPAI-UC
[0383] - Emergency NRS
[0384] - Abdominal pain NRS
[0385] Proportion of UC-related hospitalizations
[0386] Proportion of subjects requiring UC-related surgery, including colectomy
[0387] Plasma concentrations of Compound 1, M3, and other metabolites of interest (if indicated) will be determined based on samples collected prior to and 4 hours (±15 minutes) after dosing (following a 12-lead ECG) at Week 0 / Day 1
[0388] Plasma concentrations of Compound 1, M3, and other metabolites of interest (if indicated) will be determined based on samples collected prior to dosing at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52
[0389] Change from baseline in fecal calprotectin levels at Weeks 4, 8, 12, 24, and 52.
[0390] Change from baseline in hs-CRP levels at weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52.
[0391] Change from baseline in lymphocyte count at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52.
[0392] The incidence and severity of laboratory abnormalities and changes from baseline in laboratory values (including hematology, serum chemistry, coagulation, and urinalysis)
[0393] The incidence and changes from baseline in clinically significant vital sign abnormalities
[0394] Evaluations will be performed at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52. Eligible participants will be given the opportunity to enter an open-label extension (OLE) of Compound 1.
[0395] Other uses of the disclosed methods will become apparent to those skilled in the art, particularly based on a review of this patent document.
[0396] This application also includes the following specific implementation schemes:
[0397] 1. A method for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related condition in a subject in need thereof, comprising the steps of:
[0398] selecting an individual who has not been previously treated with a therapeutically effective amount of an integrin receptor antagonist; and
[0399] The subject is administered a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0400] 2. A method for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related condition in a subject in need thereof, comprising the steps of:
[0401] selecting individuals who have not been previously treated with an integrin receptor antagonist; and
[0402] The subject is administered a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0403] 3. A method for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related condition in a subject in need thereof, comprising the steps of:
[0404] determining whether the individual has been treated with an integrin receptor antagonist; and
[0405] Where the subject has not been treated with the integrin receptor antagonist, administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1; or
[0406] Where the subject is already being treated with the integrin receptor antagonist, the standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof is not administered to the subject in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0407] 4. A method for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related condition in a subject in need thereof, comprising the steps of:
[0408] Selecting individuals who do not have pancolitis; and
[0409] The subject is administered a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0410] 5. A method for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related condition in a subject in need thereof, comprising the steps of:
[0411] Select individuals without a history of pancolitis; and
[0412] The subject is administered a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0413] 6. A method for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related condition in a subject in need thereof, comprising the steps of:
[0414] Determine if the individual has a history of pancolitis; and
[0415] In the case where the subject does not have a history of pancolitis, administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1; or
[0416] In cases where the subject has a history of pancolitis, the standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof is not administered to the subject in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0417] 7. A method for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related condition in a subject in need thereof, comprising the steps of:
[0418] selecting an individual who has been previously treated with a therapeutically effective amount of an integrin receptor antagonist; and
[0419] The subject is administered a dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in excess of a standard dose.
[0420] 8. A method for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related condition in a subject in need thereof, comprising the steps of:
[0421] determining whether the individual has been treated with an integrin receptor antagonist; and
[0422] Where the subject has not been treated with the integrin receptor antagonist, administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1; or
[0423] Where the subject has been treated with the integrin receptor antagonist, the subject is administered (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in excess of the standard dose.
[0424] 9. A method for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related condition in a subject in need thereof, comprising the steps of:
[0425] Select individuals with pancolitis or a history of pancolitis; and
[0426] The subject is administered a dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in excess of a standard dose.
[0427] 10. A method for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related condition in a subject in need thereof, comprising the steps of:
[0428] Determining whether an individual has pancolitis or a history of pancolitis; and
[0429] In the case where the subject does not have a history of pancolitis, administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1; or
[0430] Where the subject has a history of pancolitis, the subject is administered (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in excess of the standard dose.
[0431] 11. A method of treating a subject with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof, comprising the steps of:
[0432] Select individuals with ulcerative proctitis, proctosigmoiditis, or left-sided colitis; and
[0433] The subject is administered a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0434] 12. A method of treating a subject with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof, comprising the steps of:
[0435] selecting individuals having a baseline lymphocyte count of at least about 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, or 1000 lymphocytes per microliter; and
[0436] The subject is administered a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0437] 13. A method for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related condition in a subject in need thereof, comprising the steps of:
[0438] determining whether the individual has a baseline lymphocyte count of at least about 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, or 1000 lymphocytes per microliter; and
[0439] administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1, where the subject has a baseline lymphocyte count of at least about 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, or 1000 lymphocytes per microliter; or
[0440] The standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof is not administered to the subject in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1 if the subject does not have a baseline lymphocyte count of at least about 500, 550, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975 or 1000 lymphocytes per microliter.
[0441] 14. A method of treating a subject with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof, comprising the steps of:
[0442] Selecting individuals who have been exposed to less than or equal to two biological agents; and
[0443] The subject is administered a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0444] 15. A method for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related condition in a subject in need thereof, comprising the steps of:
[0445] determining how many biologic agents an individual has been exposed to prior to treatment with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and
[0446] Where the subject has been exposed to less than or equal to two biologic agents, administering to the subject a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1; or
[0447] Where the subject has been exposed to more than two biologic agents, the standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof is not administered to the subject in an amount equivalent to about 0.5 mg to about 5.0 mg of Compound 1.
[0448] 16. The method of any one of the preceding specific embodiments, wherein the individual with a history of pancolitis has had pancolitis for about or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 years.
[0449] 17. The method of any one of the preceding specific embodiments, wherein the individual with a history of pancolitis has had pancolitis for about or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 years.
[0450] 18. The method of any one of the preceding specific embodiments, wherein the individual with a history of pancolitis has had pancolitis for about or greater than about 8 years.
[0451] 19. The method according to any one of the preceding specific embodiments, wherein the individual with a history of pancolitis has had pancolitis for about or greater than about 8 years.
[0452] 20. The method according to any one of the preceding specific embodiments, wherein the integrin receptor antagonist is vedolizumab.
[0453] 21. The method according to the preceding specific embodiments, wherein the therapeutically effective amount of vedolizumab is at least 300 mg.
[0454] 22. The method according to any of the preceding specific embodiments, wherein treatment comprises inducing and / or maintaining a clinical response; improving the endoscopic appearance of the mucosa; and / or inducing and / or maintaining clinical remission.
[0455] 23. The method according to any one of the preceding specific embodiments, wherein the standard dose is administered without titration.
[0456] 24. The method according to any one of the preceding specific embodiments, wherein the S1P1 receptor-associated disorder is inflammatory bowel disease.
[0457] 25. The method according to any one of the preceding specific embodiments, wherein the inflammatory bowel disease is ulcerative conjunctivitis.
[0458] 26. The method according to any one of the preceding specific embodiments, wherein the inflammatory bowel disease is moderately to severely active ulcerative conjunctivitis.
[0459] 27. The method according to any one of the preceding specific embodiments, wherein the inflammatory bowel disease is Crohn's disease.
[0460] 28. The method according to any one of the preceding specific embodiments, wherein the inflammatory bowel disease is selected from one or more of the following: ulcerative proctitis, proctosigmoiditis, and left-sided colitis.
[0461] 29. The method according to any one of the preceding specific embodiments, wherein said subject has a 3-component Mayo Clinic score of at least 6 prior to said administration.
[0462] 30. The method according to any one of the preceding specific embodiments, wherein the administration results in an improvement in the subject's 3-point Mayo Clinic score.
[0463] 31. The method according to any one of the preceding specific embodiments, wherein the administration results in an improvement in the subject's 2-part Mayo Clinic score.
[0464] 32. The method according to any one of the preceding specific embodiments, wherein the administration results in an improvement in the subject's Total Mayo Clinic Score.
[0465] 33. The method of any one of the preceding specific embodiments, wherein the administration results in an improvement in the endoscopic appearance of a mucosa of the subject.
[0466] 34. The method according to any one of the preceding specific embodiments, wherein said administration results in inducing clinical remission in said individual.
[0467] 35. The method according to any one of the preceding specific embodiments, wherein the administration results in maintenance of clinical remission in the individual.
[0468] 36. The method according to any one of the preceding specific embodiments, wherein said administration results in inducing and maintaining clinical remission in said individual.
[0469] 37. The method according to any one of the preceding specific embodiments, wherein the administration results in inducing a clinical response in the individual.
[0470] 38. The method according to any one of the preceding specific embodiments, wherein the administration results in maintenance of a clinical response in the individual.
[0471] 39. The method according to any one of the preceding specific embodiments, wherein said administration results in inducing and maintaining a clinical response in said individual.
[0472] 40. The method according to any one of the preceding specific embodiments, wherein not administering the standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof to the subject is administering to the subject more than the standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
[0473] 41. The method according to any one of the preceding specific embodiments, wherein not administering the standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof to the subject is not administering (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate, or hydrate thereof to the subject.
[0474] 42. The method according to any one of the preceding specific embodiments, wherein the amount of the standard dose is equivalent to 1 mg of Compound 1.
[0475] 43. The method according to any one of the preceding specific embodiments, wherein the amount of the standard dose is equivalent to 2 mg of Compound 1.
[0476] 44. The method according to any one of the preceding specific embodiments, wherein the amount of the standard dose is equivalent to 3 mg of Compound 1.
[0477] 45. The method according to any one of the preceding specific embodiments, wherein the standard dose of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is administered to the subject once daily.
[0478] 46. The method according to any one of the preceding specific embodiments, wherein the Compound 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof is administered orally.
[0479] 47. The method according to any one of the preceding specific embodiments, wherein the Compound 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof is formulated as a capsule or tablet suitable for oral administration.
[0480] 48. The method according to any one of the preceding specific embodiments, wherein the compound 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof is selected from:
[0481] Compound 1;
[0482] The calcium salt of Compound 1; and
[0483] L-arginine salt of compound 1.
[0484] 49. The method according to any one of the preceding specific embodiments, wherein the Compound 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof is an L-arginine salt of Compound 1.
[0485] 50. The method according to any one of the preceding specific embodiments, wherein the Compound 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof is an anhydrous non-solvated crystalline form of the L-arginine salt of Compound 1.
[0486] 51. The method according to any one of the preceding specific embodiments, wherein the Compound 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof is an anhydrous non-solvated crystalline form of Compound 1.
[0487] 52. The method of any of the preceding specific embodiments, wherein the individual has a baseline lymphocyte count of at least about 800, 825, 850, 875, 900, 925, 950, 975, or 1000 lymphocytes per microliter.
[0488] 53. The method of any one of the preceding specific embodiments, wherein the individual has been exposed to less than or equal to one biological agent.
[0489] 54. The method according to any one of the preceding specific embodiments, wherein the individual has been exposed to a Janus kinase (JAK) inhibitor approved for the treatment of ulcerative colitis.
[0490] 55. The method according to any one of the preceding specific embodiments, wherein the biologic agent is selected from golimumab, infliximab, adalimumab, vedolizumab, ustekinumab, and edelizumab.
Claims
1. Use of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in the preparation of a medicament for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related symptom in an individual in need thereof and the medicament results in an improvement in the 3-component Mayo Clinic score, the 2-component Mayo Clinic score and / or the total Mayo Clinic score of the individual, wherein the sphingosine 1-phosphate subtype 1 (S1P1) receptor-related symptom is inflammatory bowel disease, The individual has not been previously treated with a therapeutically effective amount of an integrin receptor antagonist; and The drug had an amount equivalent to about 2 mg of Compound 1.
2. The use according to claim 1, wherein the integrin receptor antagonist is vedolizumab.
3. Use of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof in the preparation of a medicament for treating a sphingosine 1-phosphate subtype 1 (S1P1) receptor-related symptom in an individual in need thereof and the medicament results in an improvement in the 3-component Mayo Clinic score, the 2-component Mayo Clinic score and / or the total Mayo Clinic score of the individual, wherein the sphingosine 1-phosphate subtype 1 (S1P1) receptor-related symptom is inflammatory bowel disease, The subject is a subject without a history of pancolitis; and the medicament has an amount equivalent to about 2 mg of Compound 1.
4. The use of claim 3, wherein the individual with a history of pancolitis has had pancolitis for about or greater than about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 years.
5. The use according to any one of claims 1 to 4, wherein the treatment comprises inducing and / or maintaining a clinical response; improving the endoscopic appearance of the mucosa; and / or inducing and / or maintaining clinical remission.
6. The use according to any one of claims 1 to 4, wherein the standard dose is administered without titration.
7. The use according to any one of claims 1 to 4, wherein the inflammatory bowel disease is ulcerative conjunctivitis.
8. The use according to any one of claims 1 to 4, wherein the inflammatory bowel disease is moderately to severely active ulcerative conjunctivitis.
9. The use according to any one of claims 1 to 4, wherein the inflammatory bowel disease is Crohn's disease.
10. The use according to any one of claims 1-4, wherein the medicament is administered to the subject once daily.
11. The use according to any one of claims 1 to 4, wherein the compound 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof is selected from: Compound 1; a calcium salt of compound 1; and L-arginine salt of compound 1.
12. The use according to any one of claims 1 to 4, wherein the Compound 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof is an L-arginine salt of Compound 1.
13. The use according to any one of claims 1 to 4, wherein the Compound 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof is an anhydrous non-solvated crystalline form of the L-arginine salt of Compound 1.
14. The use according to any one of claims 1 to 4, wherein the Compound 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof is an anhydrous non-solvated crystalline form of Compound 1.
Citation Information
Patent Citations
Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof
CN109068651A
Prevention and Treatment of Thromboembolic Disorders
US20090004265A1
SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
WO2010011316A1
Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-YL)acetic acid and salts thereof
WO2011094008A1
